{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:11:00Z","timestamp":1790856660350,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020412","name":"Humanitas Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.autrev.2026.104092","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:08:14Z","timestamp":1779952094000},"page":"104092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter"],"prefix":"10.1016","volume":"25","author":[{"given":"Marta","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tonutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.autrev.2026.104092_bb0005","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104092_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2025.11.047","article-title":"Systemic sclerosis-associated interstitial lung disease: what we know and how to incorporate guidelines into clinical practice","author":"Esposito","year":"2025","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.autrev.2026.104092_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003658","article-title":"Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort","volume":"10","author":"Scheidegger","year":"2024","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.autrev.2026.104092_bb0020","first-page":"57","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"G","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2026.104092_bb0025","first-page":"5","article-title":"Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early-onset progressive systemic sclerosis-related interstitial lung disease","author":"Potjewijd","year":"2022","journal-title":"J Transl Autoimmun"},{"issue":"12","key":"10.1016\/j.autrev.2026.104092_bb0030","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/thorax-2023-220541","article-title":"Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis","volume":"78","author":"Guler","year":"2023","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.autrev.2026.104092_bb0035","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ard.2025.01.014","article-title":"Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database","volume":"84","author":"Yan","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104092_bb0040","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000002249","article-title":"Therapeutic choices in systemic sclerosis-associated interstitial lung disease, a survey of 2 international research groups","volume":"31","author":"MacKlin","year":"2025","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104092_bb0045","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.autrev.2026.104092_bb0050","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01368-2024","article-title":"Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial","volume":"64","author":"Mansy","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2026.104092_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103492","article-title":"Evaluation of the mycophenolate mofetil\u2013rituximab combination in systemic sclerosis: a French retrospective multicenter study (MycRiSSc)","volume":"157","author":"Barde","year":"2025","journal-title":"J Autoimmun"},{"issue":"SI","key":"10.1016\/j.autrev.2026.104092_bb0060","doi-asserted-by":"crossref","first-page":"SI184","DOI":"10.1093\/rheumatology\/keaf006","article-title":"Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis","volume":"64","author":"Goldman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104092_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1569501","article-title":"Breaking the cycle: should we target inflammation, fibrosis, or both?","volume":"16","author":"Baxter","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104092_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12016-023-08969-x","article-title":"Treatable traits in systemic sclerosis","volume":"65","author":"Amati","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"26","key":"10.1016\/j.autrev.2026.104092_bb0075","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.autrev.2026.104092_bb0080","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104092_bb0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104092_bb0090","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104092_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104092_bb0100","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02533-2024","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease","volume":"67","author":"Antoniou","year":"2026","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.autrev.2026.104092_bb0105","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Van Den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104092_bb0110","article-title":"Correspondence to: \u2018Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.\u2019","author":"Yang","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104092_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/art.70043","article-title":"Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database","author":"Campochiaro","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104092_bb0120","article-title":"Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): a double-blind placebo-controlled randomiz\u2026","volume":"78","author":"Bejan-Angoulvant","year":"2020","journal-title":"Respir Med Res"},{"key":"10.1016\/j.autrev.2026.104092_bb0125","doi-asserted-by":"crossref","unstructured":"De Lorenzis E, Parente P, Soldati S, Barbara A, Natalello G, Davoli M, et al. Rising incidence of systemic autoimmune inflammatory rheumatic diseases during the COVID-19 pandemic: a geographical cohort study [Internet]. doi:https:\/\/doi.org\/10.1136\/rmdopen-2024-005227.","DOI":"10.1136\/rmdopen-2024-005227"},{"key":"10.1016\/j.autrev.2026.104092_bb0130","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211032437","article-title":"Interstitial lung disease pathology in systemic sclerosis","volume":"13","author":"Konopka","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:30:04Z","timestamp":1790494204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1568997226001060"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104092","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104092"}}